News & Updates

Show Multimedia Only
Amivantamab/lazertinib combo shows promise in EGFR-mutated NSCLC

Amivantamab/lazertinib combo shows promise in EGFR-mutated NSCLC

10 Dec 2022 byTristan Manalac

Among nonsmall cell lung cancer (NSCLC) patients with mutations spanning exons 18 to 21, combination treatment with amivantamab and lazertinib induces high rates of response, reports a study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).

10 Dec 2022